{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.1","value":"43.57"},{"groupId":"OG001","spread":"21.5","value":"64.45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered 2.5 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 1: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Escalation"},{"description":"Participants were administered 3.4 mg/kg of belantamab mafodotin in combination with 200 mg of pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal , or for a maximum of 35 cycles.","id":"OG001","title":"Part 1: Belantamab Mafodotin 3.4 mg/kg + Pembrolizumab 200 mg Escalation"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Population. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, EOI, 2, 4, 9, and 24 hour post-SOI on Cycle 1 Day 1, Cycle 1 Day 4, Cycle 1 Day 8, and pre-dose on Cycle 2 Day 1","title":"Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose","type":"SECONDARY","unitOfMeasure":"ug/mL"}